Writer says equipping AED first-aid boxes with easy administration of epinephrine and naloxone could save more lives.

The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...

Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

This new evidence raises worries about the spread of AGS, particularly in regions like Long Island, where ticks are a growing ...

Aquestive Therapeutics leverages its PharmFilm technology to develop innovative oral drug delivery systems. Find out why I'm neutral on AQST stock.

Symptoms that warrant immediate emergency care, from chest pain to severe allergic reactions, and when urgent care or ...

The maker of a new prescription drug product for people with life-threatening allergies is using copayment coupons to build ...

Eric Karas, Chief Commercial Officer, outlined the company's multi-pronged strategy to increase neffy adoption, focusing on education, payer coverage, and patient awareness. He noted that neffy ...

ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and strategic advancements in global commercialization, despite challenges in market adoption.